Urogen Pharma Ltd Stock

$16.20+0.41 (+2.6%)
Updated Jul 22, 2024
URGN Price
Fair Value Price
Market Cap
52 Week Low
52 Week High
Dividend Yield
Gross Margin
Operating Margin
Profit Margin
Debt to Equity
Operating Cash Flow
Next Earnings
Aug 8, 2024
Next Dividend

URGN Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how URGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

URGN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
URGN is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
URGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more URGN due diligence checks available for Premium users.

Be the first to know about important URGN news, forecast changes, insider trades & much more!



URGN price to earnings (PE)

For valuing profitable companies with steady earnings

URGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

URGN's financial health

Profit margin

Net Income
Profit Margin
URGN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
URGN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Debt to equity
URGN's short-term assets ($196.76M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
URGN's long-term liabilities ($214.37M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
URGN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
URGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

URGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

URGN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B

Urogen Pharma Stock FAQ

What is Urogen Pharma's quote symbol?

(NASDAQ: URGN) Urogen Pharma trades on the NASDAQ under the ticker symbol URGN. Urogen Pharma stock quotes can also be displayed as NASDAQ: URGN.

If you're new to stock investing, here's how to buy Urogen Pharma stock.

What is the 52 week high and low for Urogen Pharma (NASDAQ: URGN)?

(NASDAQ: URGN) Urogen Pharma's 52-week high was $24.13, and its 52-week low was $8.69. It is currently -32.86% from its 52-week high and 86.42% from its 52-week low.

How much is Urogen Pharma stock worth today?

(NASDAQ: URGN) Urogen Pharma currently has 36,130,121 outstanding shares. With Urogen Pharma stock trading at $16.20 per share, the total value of Urogen Pharma stock (market capitalization) is $585.31M.

Urogen Pharma stock was originally listed at a price of $13.98 in May 4, 2017. If you had invested in Urogen Pharma stock at $13.98, your return over the last 7 years would have been 15.88%, for an annualized return of 2.13% (not including any dividends or dividend reinvestments).

How much is Urogen Pharma's stock price per share?

(NASDAQ: URGN) Urogen Pharma stock price per share is $16.20 today (as of Jul 22, 2024).

What is Urogen Pharma's Market Cap?

(NASDAQ: URGN) Urogen Pharma's market cap is $585.31M, as of Jul 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Urogen Pharma's market cap is calculated by multiplying URGN's current stock price of $16.20 by URGN's total outstanding shares of 36,130,121.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.